Free Trial

Scancell (SCLP) Competitors

Scancell logo
GBX 9.90 -0.10 (-1.00%)
As of 10:37 AM Eastern

SCLP vs. PRTC, OXB, HZD, FARN, VRP, ARIX, BVXP, 4BB, CIR, and HVO

Should you be buying Scancell stock or one of its competitors? The main competitors of Scancell include PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), 4basebio (4BB), Circassia Group (CIR), and hVIVO (HVO). These companies are all part of the "biotechnology" industry.

Scancell vs.

Scancell (LON:SCLP) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Scancell has higher earnings, but lower revenue than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ScancellN/AN/A-£6.75M-£0.65-15.18
PureTech Health£521.32K774.40-£91.86M-£24.38-5.51

Scancell has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

PureTech Health received 343 more outperform votes than Scancell when rated by MarketBeat users. Likewise, 86.60% of users gave PureTech Health an outperform vote while only 74.50% of users gave Scancell an outperform vote.

CompanyUnderperformOutperform
ScancellOutperform Votes
187
74.50%
Underperform Votes
64
25.50%
PureTech HealthOutperform Votes
530
86.60%
Underperform Votes
82
13.40%

46.5% of Scancell shares are owned by institutional investors. Comparatively, 79.9% of PureTech Health shares are owned by institutional investors. 5.0% of Scancell shares are owned by insiders. Comparatively, 15.9% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PureTech Health has a consensus target price of GBX 455, indicating a potential upside of 238.54%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Scancell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scancell
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
PureTech Health
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Scancell had 3 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Scancell and 1 mentions for PureTech Health. Scancell's average media sentiment score of 0.90 beat PureTech Health's score of 0.00 indicating that Scancell is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scancell
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PureTech Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Scancell has a net margin of 0.00% compared to PureTech Health's net margin of -17,620.94%. Scancell's return on equity of 98.74% beat PureTech Health's return on equity.

Company Net Margins Return on Equity Return on Assets
ScancellN/A 98.74% -45.28%
PureTech Health -17,620.94%-21.15%-13.39%

Summary

PureTech Health beats Scancell on 11 of the 17 factors compared between the two stocks.

Get Scancell News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLP vs. The Competition

MetricScancellBiotechnology IndustryMedical SectorLON Exchange
Market Cap£102.54M£128.53M£5.33B£2.66B
Dividend YieldN/A3.74%5.21%5.05%
P/E Ratio-15.183.4026.71129.21
Price / SalesN/A4,120.92386.12221,406.01
Price / Cash7.8613.1938.2528.02
Price / Book-25.4033.136.773.79
Net Income-£6.75M-£91.56M£3.23B£5.88B
7 Day Performance7.61%2.85%1.80%0.63%
1 Month Performance-15.02%7.93%11.10%22.11%
1 Year Performance-1.98%99.18%17.11%120.87%

Scancell Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLP
Scancell
N/AGBX 9.90
-1.0%
N/A-2.0%£102.54MN/A-15.1851News Coverage
Insider Trade
PRTC
PureTech Health
1.3353 of 5 stars
GBX 135
+4.3%
GBX 455
+237.0%
-40.3%£405.51M£521,320.79-5.54300
OXB
Oxford Biomedica
2.1895 of 5 stars
GBX 304.50
-1.0%
GBX 380
+24.8%
-8.1%£323.69M£98.31M-2.26891
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
FARN
Faron Pharmaceuticals Oy
N/AGBX 223
+0.9%
N/A-6.3%£299.38MN/A-5.9634Gap Up
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
BVXP
Bioventix
N/AGBX 2,890
-2.0%
N/A-33.9%£151.33M£13.65M18.6912News Coverage
4BB
4basebio
N/AGBX 1,145
+1.8%
GBX 1,600
+39.7%
-18.5%£146.67M£311,000.00-1,467.95101News Coverage
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down
HVO
hVIVO
N/AGBX 17.15
-2.0%
N/A-35.3%£121.35M£68.74M7.07N/AGap Down

Related Companies and Tools


This page (LON:SCLP) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners